Crucial Innovations Narrows Loss Amidst Zero Revenue, Rising Debt

TL;DR

**Crucial Innovations is burning cash with zero revenue, relying heavily on related party financing, making it a highly speculative bet on future cannabis sales.**

AI Summary

Crucial Innovations Corp. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year. The company experienced a net loss of $2,564,897 for the three months ended June 30, 2025, a significant improvement from the $6,727,320 net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $4,877,084, substantially lower than the $89,813,364 net loss reported for the six months ended June 30, 2024. Total operating expenses decreased dramatically to $2,570,620 for the three months ended June 30, 2025, from $6,725,088 in 2024, and to $4,870,923 for the six months ended June 30, 2025, from $89,810,260 in 2024. This reduction was primarily driven by lower professional fees and management fees compared to the prior year, which included substantial stock-based compensation. Cash decreased from $52,668 at December 31, 2024, to $34,949 at June 30, 2025. The company's total liabilities increased to $2,932,011 at June 30, 2025, from $1,871,473 at December 31, 2024, largely due to an increase in 'Due to related parties' to $1,818,514 and the introduction of $322,879 in convertible notes.

Why It Matters

This filing reveals a company in a precarious position, having generated no revenue while still incurring significant operating losses, albeit reduced from the prior year. For investors, the lack of commercial sales in its medical cannabis venture, despite strategic acquisitions like Ember Pharms (Pty) Ltd. and a joint venture with Inspire Pharmacy, signals a high-risk investment. Employees might face uncertainty given the company's inability to generate revenue. Customers are not yet impacted as the company has not achieved commercial sales. The broader market for medical cannabis distribution in the UK and Europe sees a potential new entrant struggling to launch, highlighting the challenges in this competitive and regulated sector. The substantial increase in 'Due to related parties' and new convertible notes also raises concerns about financing stability and potential dilution.

Risk Assessment

Risk Level: high — The company reported no revenue for the three and six months ended June 30, 2025, and has an accumulated deficit of $96,180,007. Total liabilities increased to $2,932,011 from $1,871,473 in six months, with 'Due to related parties' reaching $1,818,514, indicating significant reliance on insider funding and a weak financial position.

Analyst Insight

Investors should exercise extreme caution and avoid Crucial Innovations Corp. until it demonstrates a clear path to revenue generation and sustainable operations. The current financial state, characterized by zero revenue and increasing liabilities, suggests a high probability of further dilution or financial distress.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$346,590

total Debt

$2,932,011

net Income

$(2,564,897)

eps

N/A

gross Margin

N/A

cash Position

$34,949

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (for three and six months ended June 30, 2025, indicating no commercial sales)
• $(2,564,897) — Net Loss (Q2 2025) (improved from $(6,727,320) in Q2 2024)
• $(4,877,084) — Net Loss (YTD Q2 2025) (significantly improved from $(89,813,364) in YTD Q2 2024)
• $34,949 — Cash (as of June 30, 2025, down from $52,668 at December 31, 2024)
• $2,932,011 — Total Liabilities (as of June 30, 2025, up from $1,871,473 at December 31, 2024)
• $1,818,514 — Due to related parties (as of June 30, 2025, up from $1,052,743 at December 31, 2024)
• $322,879 — Convertible notes (new liability as of June 30, 2025)
• 391,216,894 — Common shares outstanding (as of June 30, 2025, up from 381,320,798 at December 31, 2024)

Key Players & Entities

• Crucial Innovations Corp. (company) — registrant
• Ember Pharms (Pty) Ltd. (company) — acquired medical cannabis grower
• Inspire Pharmacy (company) — UK licensed pharmacy and joint venture partner
• Crop Circle Dispensary Limited (company) — joint venture entity
• Tomanic Trading (Pty) Ltd (company) — medical cannabis supplier
• Securities and Exchange Commission (regulator) — filing oversight
• Nevada (regulator) — state of incorporation
• United Kingdom (regulator) — primary market for medical cannabis distribution

FAQ

Risk Factors

• Deteriorating Cash Position and Increasing Liabilities [high — financial]: The company's cash decreased from $52,668 at December 31, 2024, to $34,949 at June 30, 2025. Concurrently, total liabilities increased significantly to $2,932,011 from $1,871,473, driven by a rise in 'Due to related parties' to $1,818,514 and the issuance of $322,879 in convertible notes. This trend indicates a worsening financial condition and potential future repayment challenges.
• Continued Lack of Revenue Generation [high — operational]: Crucial Innovations Corp. reported zero revenue for both the three and six months ended June 30, 2025. This lack of commercial sales, consistent with the prior year, raises serious concerns about the company's business model viability and its ability to generate income from its operations.
• Substantial Accumulated Deficit [high — financial]: The company has accumulated a deficit of $96,180,007 as of June 30, 2025. This substantial deficit, coupled with a negative total stockholders' equity of $2,585,421, highlights a history of unprofitability and significant financial challenges.
• Reliance on Related Party Financing [medium — financial]: The significant increase in 'Due to related parties' to $1,818,514 suggests a heavy reliance on financing from affiliated entities. This concentration of debt could pose risks if these related parties withdraw support or demand repayment under unfavorable terms.
• Issuance of Convertible Notes [medium — financial]: The introduction of $322,879 in convertible notes as a new liability introduces potential future dilution for common shareholders if converted. It also adds to the company's debt burden and interest expense.
• High Marketing Expenses in Prior Periods [low — operational]: While operating expenses have decreased, the prior year's six-month period included $5,332,751 in marketing expenses. The current period shows a drastic reduction to $74,567. The sustainability of this reduced marketing spend and its impact on future growth are unclear.
• Significant Reduction in Professional and Management Fees [low — operational]: The dramatic decrease in operating expenses is attributed to lower professional and management fees, which included substantial stock-based compensation in the prior year. While this improves current losses, it may indicate a reduction in essential services or a change in compensation structure that needs further scrutiny.

Industry Context

Crucial Innovations Corp. operates in a highly competitive landscape where innovation and market penetration are critical for success. Companies in this sector often face long development cycles and significant R&D costs before generating revenue. The current trend towards digital transformation and specialized solutions presents opportunities, but also requires substantial investment and effective go-to-market strategies.

Regulatory Implications

As a company with no reported revenue, Crucial Innovations Corp. may face scrutiny regarding its business model and financial sustainability from regulatory bodies. Compliance with financial reporting standards and disclosure requirements is paramount, especially given the increasing liabilities and related party transactions.

What Investors Should Do

1. Monitor future filings for any signs of revenue generation or a clear path to commercialization.
2. Investigate the nature and terms of the 'Due to related parties' and convertible notes to understand repayment obligations and potential dilution.
3. Assess the company's strategy for managing its cash burn and improving its financial position given the declining cash reserves and increasing liabilities.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported $0 revenue, a net loss of $2,564,897, and cash of $34,949. Total liabilities increased to $2,932,011.
• 2024-06-30: End of Q2 2024 — Reported $0 revenue and a net loss of $6,727,320. Operating expenses were $6,725,088.
• 2024-12-31: End of Fiscal Year 2024 — Cash was $52,668 and total liabilities were $1,871,473.

Glossary

Accumulated deficit

The total net losses of a company over its lifetime that have not been offset by net income. (Indicates the company's historical unprofitability, standing at $96,180,007 as of June 30, 2025.)

Due to related parties

Amounts owed by the company to individuals or entities that have a close relationship with the company, such as major shareholders or management. (This liability increased significantly to $1,818,514, highlighting potential reliance on related party financing.)

Convertible notes

Debt instruments that can be converted into a predetermined amount of equity in the issuing company. (A new liability of $322,879 was introduced, posing potential future dilution and adding to debt obligations.)

Stock-based compensation

Compensation provided to employees in the form of stock options or shares, rather than cash. (A significant factor in the prior year's higher operating expenses, its reduction contributed to the improved net loss in the current period.)

Stockholders' Deficit

The negative value of a company's equity when liabilities exceed assets. (The company has a total stockholders' deficit of $2,585,421 as of June 30, 2025, indicating liabilities outweigh assets.)

Year-Over-Year Comparison

Compared to the prior year, Crucial Innovations Corp. has shown a dramatic reduction in its net loss for both the three-month and six-month periods ended June 30, 2025. This improvement is primarily driven by a significant decrease in operating expenses, particularly professional and management fees, which were substantially higher in the prior year due to stock-based compensation. However, revenue remains at $0, and the company's cash position has declined while total liabilities have increased, indicating ongoing financial challenges despite the improved loss figures.

Key Financial Figures

• $0.001 — of the registrant’s common stock, $0.001 par value, outstanding, as of June 30 ,
• $0 — k: 500,000,000 authorized; par value of $0.001, 391,216,894 shares and 381,320,798
• $208 — 8 - Cash, end of period $ 34,949 $208 Supplemental cash flow information:
• $194,869 — on Ember Pharms (Pty) Ltd. $ — $194,869 The accompanying notes are an integra
• $34,949 — ember 31, 2024. The Company had cash of $34,949 and $52,668, as of June 30, 2025, and D
• $52,668 — 24. The Company had cash of $34,949 and $52,668, as of June 30, 2025, and December 31,
• $250,000 — ore than the federally insured limit of $250,000 per institution. The Company has not ex

Filing Documents

• f10q_cinv06302025.htm (10-Q) — 571KB
• ex311_302ceocertification.htm (EX-31.1) — 11KB
• ex312_302cfocertification.htm (EX-31.2) — 10KB
• ex321_906ceocertification.htm (EX-32.1) — 5KB
• ex322_906cfocertification.htm (EX-32.2) — 5KB
• 0001712543-25-000069.txt ( ) — 603KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (unaudited)

Item 1. Condensed Consolidated Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Stockholders’ Deficit 5 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8

. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 2 . Management’s Discussion and Analysis of Financial Condition and Results of Operations 21

. Quantitative and Qualitative Disclosures about Market Risk

Item 3 . Quantitative and Qualitative Disclosures about Market Risk 26

. Controls and Procedures

Item 4 . Controls and Procedures 26

OTHER INFORMATION

PART II. OTHER INFORMATION

. Legal Proceedings

Item 1 . Legal Proceedings 27

Risk Factors

Item 1A. Risk Factors 27

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 28

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 28

Other Information

Item 5. Other Information 28

Exhibits

Item 6. Exhibits 29

SIGNATURES

SIGNATURES 30 2 Table of Contents

Financial Information

Part I. Financial Information

Consolidated Condensed Financial Statements (Unaudited)

Item 1. Consolidated Condensed Financial Statements (Unaudited) CRUCIAL INNOVATIONS CORP. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) June 30, December 31, 2025 2024 ASSETS Current Assets Cash $ 34,949 $ 52,668 VAT receivable 24,760 15,605 Prepaid expenses — 12 Advances to supplier 221,626 — Other receivable 2,265 — Total Current Assets 283,600 68,285 Intangible assets, net — — Property and equipment, net 26,828 23,306 Restricted cash 36,162 — Total Assets $ 346,590 $ 91,591 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable and accrued liabilities $ 690,335 $ 784,788 Contract advances 100,283 33,942 Due to related parties 1,818,514 1,052,743 Total Current Liabilities 2,609,132 1,871,473 Convertible notes 322,879 — Total Liabilities 2,932,011 1,871,473 Commitments and contingencies — — Stockholders' Deficit Preferred stock: 50,000,000 authorized; $0.001 par value, no shares issued and outstanding — — Common stock: 500,000,000 authorized; par value of $0.001, 391,216,894 shares and 381,320,798 shares issued and outstanding at June 30,2025 and December 31,2024, respectively 391,217 381,321 Additional paid-in capital 93,251,017 89,117,267 Accumulated deficit (96,180,007 ) (91,302,923 ) Accumulated other comprehensive loss (47,648 ) 24,453 Total Stockholders' Deficit (2,585,421 ) (1,779,882 ) Total Liabilities and Stockholders' Deficit $ 346,590 $ 91,591 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents CRUCIAL INNOVATIONS CORP. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) For the For the Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue

View Full Filing

View this 10-Q filing on SEC EDGAR